Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Present at Hep-DART 2023

Thursday, November 30, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. will present at Hep-DART 2023, showcasing its innovative ARCUS® platform. This platform is designed for in vivo gene editing therapies, enabling sophisticated gene edits such as insertion, excision, and elimination. The presentation highlights the company's advancements in gene editing technology.
Price reaction · baseline $11.841 (2023-11-30T17:59:00.000Z) · hit during market hours · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-10%
day 1
-7.5%
day 3
+2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is presenting at a notable event.
  • The company is advancing gene editing therapies.
  • Utilizes a novel proprietary ARCUS® platform.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 30, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is the focus of Precision BioSciences' presentation?

The presentation will focus on their ARCUS® platform for gene editing therapies.

When is Precision BioSciences presenting?

Precision BioSciences will present at Hep-DART 2023 on November 30, 2023.

What technologies does the ARCUS® platform utilize?

The ARCUS® platform is designed for in vivo gene editing, including insertion and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Hep-DART 2023 gene editing ARCUS platform
Last updated: Nov 30, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →